Skip to main content

Advertisement

SpringerLink
Log in

Squamous Carcinoma of the Ovary

  • Gynecologic Cancers (NS Reed, Section Editor)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Squamous ovarian cancer (SOC) represents a (very) rare subtype of ovarian cancer. The lack of evidence on which to base management presents significant challenges. The small number of patients prohibits randomised studies to establish level 1 evidence, and no non-randomised studies or prospective series have been reported. Here, we present a review of the available literature on squamous ovarian cancer and explore some lessons learnt from squamous cancers originating from other primary sites to see if these can be applied to SOC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. McCluggage WG. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology. 2011;43(5):420–32.

    Article  PubMed  Google Scholar 

  2. Kobel M, Kalloger SE, Huntsman DG, et al. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol. 2010;29(3):203–11.

  3. Hackethal A, Brueggmann AD, Bohlmann MK, et al. Squamous-cell carcinoma in mature cystic teratoma of the ovary: systematic review and analysis of published data. Lancet Oncol. 2008;9(12):1173–80.

  4. Pins MR, Young RH, Daly WJ, et al. Primary squamous cell carcinoma of the ovary. Report of 37 cases. Am J Surg Pathol. 1996;20(7):823–33.

  5. AciÈn P, Abad M, Mayol MJ, et al. Primary squamous cell carcinoma of the ovary associated with endometriosis. Int J Gynaecol Obstet. 2010;108(1):16–20.

  6. Hasegawa E, Nishi H, Terauchi F, et al. A case of squamous cell carcinoma arising from endometriosis of the ovary. Eur J Gynaecol Oncol. 2011;32(5):554–6.

  7. Mahe E, Sur M. Squamous lesions of the ovary. Arch Pathol Lab Med. 2011;135(12):1611–4.

    Article  PubMed  Google Scholar 

  8. Mills SE, Carter D, Greenson JK, et al. Sternberg's diagnostic surgical pathology. In: Clement PB, Young RH, editors. Ovarian surface epithelial-stromal tumours, vol. 1. 5th ed. Baltimore: Lippincott Williams & Wilkins; 2010.

  9. Chen RJ, Chen KY, Chang TC, et al. Prognosis and treatment of squamous cell carcinoma from a mature cystic teratoma of the ovary. J Formos Med Assoc. 2008;107(11):857–68.

  10. Dos Santos L, Mok E, Iasonos A, et al. Squamous cell carcinoma arising in mature cystic teratoma of the ovary: a case series and review of the literature. Gynecol Oncol. 2007;105(2):321–4.

  11. Tseng CJ, Chou HH, Huang KG, et al. Squamous cell carcinoma arising in mature cystic teratoma of the ovary. Gynecol Oncol. 1996;63(3):364–70.

  12. Ribeiro G, Hughesdon P, Wiltshaw E. Squamous carcinoma arising in dermoid cysts and associated with hypercalcemia: a clinicopathologic study of six cases. Gynecol Oncol. 1988;29(2):222–30.

  13. Ayhan A, Tuncer ZS, Bilgin F, et al. Squamous cell carcinoma arising in dermoid cyst. Eur J Gynaecol Oncol. 1996;17(2):144–7.

  14. Stamp GW, McConnell EM. Malignancy arising in cystic ovarian teratomas. A report of 24 cases. Br J Obstet Gynaecol. 1983;90(7):671–5.

    Article  CAS  PubMed  Google Scholar 

  15. Amerigo J, Nogales FF Jr, Fernandez-Sanz J, et al. Squamous cell neoplasms arising from ovarian benign cystic teratoma. Gynecol Oncol. 1979;8(3):277–83.

  16. Hirakawa T, Tsuneyoshi M, Enjoji M. Squamous cell carcinoma arising in mature cystic teratoma of the ovary. Clinicopathologic and topographic analysis. Am J Surg Pathol. 1989;13(5):397–405.

    Article  CAS  PubMed  Google Scholar 

  17. Paliogiannis P, Cossu A, Capobianco G, et al. Squamous cell carcinoma arising in mature cystic teratoma of the ovary: report of two cases with molecular analysis. Eur J Gynaecol Oncol. 2014;35(1):72–6. This is the only existing publication describing attempts to molecularly characterize squamous ovarian cancer.

  18. Hoadley KA, Yau C, Wolf DM, et al. Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin. Cell, 2014. This is an important recent paper describing molecular characterization across tissue of origin rather than ‘within-a-tissue’.

  19. Brash DE, Rudolph JA, Simon JA, et al. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci U S A. 1991;88(22):10124–8.

  20. Gibbons DL, Byers LA, Kurie JM. Smoking, p53 mutation, and lung cancer. Mol Cancer Res. 2014;12(1):3–13.

    Article  CAS  PubMed  Google Scholar 

  21. Warren W, Biggs PJ, el-Baz M, et al. Mutations in the p53 gene in schistosomal bladder cancer: a study of 92 tumours from Egyptian patients and a comparison between mutational spectra from schistosomal and non-schistosomal urothelial tumours. Carcinogenesis. 1995;16(5):1181–9.

  22. Marur S, D'Souza G, Westra WH, et al. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol. 2010;11(8):781–9.

  23. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006;118(12):3030–44.

    Article  CAS  PubMed  Google Scholar 

  24. El-Sebaie M, Zaghloul MS, Howard G, et al. Squamous cell carcinoma of the bilharzial and non-bilharzial urinary bladder: a review of etiological features, natural history, and management. Int J Clin Oncol. 2005;10(1):20–5.

  25. Raziuddin S, Masihuzzaman M, Shetty S, et al. Tumor necrosis factor alpha production in schistosomiasis with carcinoma of urinary bladder. J Clin Immunol. 1993;13(1):23–9.

  26. Cooks T, Pateras IS, Tarcic O, et al. Mutant p53 prolongs NF-kappaB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell. 2013;23(5):634–46.

  27. Zandberg DP, Strome SE. The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck. Oral Oncol. 2014;50(7):627–32.

    Article  CAS  PubMed  Google Scholar 

  28. Hinrichs CS, Rosenberg SA. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev. 2014;257(1):56–71.

    Article  CAS  PubMed  Google Scholar 

  29. Basu P, Mehta AO, Jain MM, et al. ADXS11-001 immunotherapy targeting HPV-E7: final results from a phase 2 study in Indian women with recurrent cervical cancer. Am J Clin Oncol. 2014;32(5s):5610.

  30. Hinrichs CS, Stevanovic S, Draper L, et al. HPV-targeted tumor-infiltrating lymphocytes for cervical cancer. Am J Clin Oncol. 2014;32(5s):3008.

  31. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348(3):203–13.

  32. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10(9):942–9.

  33. Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005;102(51):18538–43.

  34. Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature. 2008;454(7203):436–44.

  35. Balkwill F, Mantovani A. Cancer and inflammation: implications for pharmacology and therapeutics. Clin Pharmacol Ther. 2010;87(4):401–6.

    Article  CAS  PubMed  Google Scholar 

  36. Stone RL, Nick AM, McNeish IA, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012;366(7):610–8.

  37. Coward J, Kulbe H, Chakravarty P, et al. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res. 2011;17(18):6083–96.

  38. Annunziata CM, Stavnes HT, Kleinberg L, et al. Nuclear factor kappaB transcription factors are coexpressed and convey a poor outcome in ovarian cancer. Cancer. 2010;116(13):3276–84.

  39. Iwasa A, Oda Y, Kurihara S, et al. Malignant transformation of mature cystic teratoma to squamous cell carcinoma involves altered expression of p53- and p16/Rb-dependent cell cycle regulator proteins. Pathol Int. 2008;58(12):757–64.

  40. Scheffner M, Werness BA, Huibregtse JM, et al. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 1990;63(6):1129–36.

  41. Scheffner M, Huibregtse JM, Vierstra RD, et al. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell. 1993;75(3):495–505.

  42. Svahn MF, Faber MT, Christensen J, et al. Prevalence of human papillomavirus in epithelial ovarian cancer tissue. A meta-analysis of observational studies. Acta Obstet Gynecol Scand. 2014;93(1):6–19.

  43. Verguts J, Amant F, Moerman P, et al. HPV induced ovarian squamous cell carcinoma: case report and review of the literature. Arch Gynecol Obstet. 2007;276(3):285–9.

  44. Fujii T, Oguni S, Kikuchi M, et al. p53 mutation in carcinomas arising in ovarian cystic teratomas. Pathol Int. 1995;45(9):649–54.

  45. Shah SP, Kobel M, Senz J, et al. Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med. 2009;360(26):2719–29.

  46. Witkowski L, Carrot-Zhang J, Albrecht S, et al. Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type. Nat Genet. 2014;46(5):438–43. This is a recent publication demonstrating that modern sequencing of even small numbers of a rare tumour type can be effective in identifying high frequency mutations.

  47. Pignon JP, le Maitre A, Maillard E, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92(1):4–14.

  48. Nogueira-Rodrigues A, Moralez G, Grazziotin R, et al. Phase 2 trial of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced cervical cancer. Cancer. 2014;120(8):1187–93.

  49. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol. 2003;21(14):2787–99.

    Article  CAS  PubMed  Google Scholar 

  50. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567–78.

  51. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11(1):21–8.

  52. Egloff AM, Lee JW, Langer C, et al., Phase II study of cetuximab in combination with cisplatin and radiation in unresectable, locally advanced head and neck squamous cell carcinoma: Eastern Cooperative Oncology Group Trial E3303. Clin Cancer Res, 2014

  53. Ford TC, Timmins PF. Successful treatment of metastatic squamous cell carcinoma of the ovary arising within a mature cystic teratoma. Clinical Ovarian Cancer. 2011;4(1):44–6.

    Article  Google Scholar 

  54. Rasila KK, Burger RA, Smith H, et al. Angiogenesis in gynecological oncology-mechanism of tumor progression and therapeutic targets. Int J Gynecol Cancer. 2005;15(5):710–26.

  55. Jackson MW, Rusthoven CG, Fisher CM, et al. Clinical potential of bevacizumab in the treatment of metastatic and locally advanced cervical cancer: current evidence. Onco Targets Ther. 2014;7:751–9.

  56. Tewari KS, Sill MW, Long HJ, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014;370(8):734–43.

  57. Argiris A, Karamouzis MV, Gooding WE, et al. Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer. J Clin Oncol. 2011;29(9):1140–5.

  58. Argiris A, Kotsakis AP, Hoang T, et al. Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck. Ann Oncol. 2013;24(1):220–5.

  59. Viloria-Petit AM, Kerbel RS. Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies. Int J Radiat Oncol Biol Phys. 2004;58(3):914–26.

    Article  CAS  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Dr. Patricia Roxburgh has received grant money from Roche for a Phase I/II Study of R05503781 and from the Academy of Medical Sciences for a pre-clinical study investigating the relationship between p53 mutations and inflammation in ovarian cancer.

Dr. Rosalind Glasspool has received grant money from Boehringer Ingelheim for a trial of Nintedanib in clear cell ovarian cancer, from Roche for a trial in women with relapsed epithelial ovarian cancer and from Lilly for a trial in platinum resistant ovarian cancer.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK

    Patricia Roxburgh

  2. The Beatson West of Scotland Cancer Centre, 1053 Great Western Road, Glasgow, G12 0YN, UK

    Patricia Roxburgh & Rosalind Glasspool

Authors
  1. Patricia Roxburgh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rosalind Glasspool
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patricia Roxburgh.

Additional information

This article is part of the Topical Collection on Gynecologic Cancers

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Roxburgh, P., Glasspool, R. Squamous Carcinoma of the Ovary. Curr Oncol Rep 16, 413 (2014). https://doi.org/10.1007/s11912-014-0413-1

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11912-014-0413-1

Keywords

Search

Navigation